) recently gained US Food and Drug Administration (FDA) approval
for its generic version of Suboxone (buprenorphine HCl and
naloxone HCl dihydrate SL tablets, 2 mg/0.5 mg and 8 mg/2
The company intends to launch its generic version of Suboxone
immediately. Suboxone, which is indicated for the
maintenance treatment of opioid dependence, posted sales of about
$625 million in the US for the 12 months ending Dec 31, 2012. The
sales data is as per IMS Health.
Actavis Pharma, the company's global generics business, is
expected to post revenues of $6.3 billion - $6.5 billion in 2013.
The segment had posted sales of $4.4 billion in 2012, up 32%.
Actavis is the third largest player in the global generics
market and has a presence in more than 60 countries. As of Dec
31, 2012, Actavis had more than 185 Abbreviated New Drug
Applications (ANDAs) pending FDA approval. These include 49
first-to-file opportunities of which 33 could be exclusive
first-to-files.The company intends to launch its generic version
) Pulmicort Respules in the second quarter of 2013. While Actavis
expects an additional competitor for generic Concerta to enter
the market in the first quarter of 2013 and a second competitor
later this year, it does not expect any competition for its
generic versions of Lidoderm and Adderall XR until 2014.
Actavis currently carries a Zacks Rank #3 (Hold). Other
generic players like
) currently look better positioned with a Zacks Rank #2 (Buy).
Meanwhile, in the pharma space,
Avanir Pharmaceuticals, Inc.
) has a Zacks Rank #2.
ACTAVIS INC (ACT): Free Stock Analysis Report
AVANIR PHARM (AVNR): Free Stock Analysis
ASTRAZENECA PLC (AZN): Free Stock Analysis
MYLAN INC (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.